4D Molecular Therapeutics
FDMT----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: 4D Molecular Therapeutics(FDMT) predict that the Revenue is 3.047 M (+217 times%), Beat estimate;the EBIT is -73.62 M (-37.3%), Miss estimate;the EPS is -1.01 (-17.44%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B21664.29%
0.00B18382.14%
+0.00B3,282.15%
EBITMiss expectations
-0.07B37.30%
-0.07B27.17%
-0.01B10.13%
EPSMiss expectations
-1.0117.44%
-0.9429.53%
-0.06807.91%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf